LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies BioTime, Inc.)
Reporting Period: Quarterly Report (Form 10-Q) for the period ended June 30, 2005.
Business Overview: BioTime is a biomedical organization engaged in the research and development of synthetic plasma expanders (Hextend, PentaLyte) and organ preservation solutions (HetaCool). The company generates revenue primarily through licensing fees and royalties from partners Hospira (US/Canada) and CJ Corp. (South Korea).

Key Financial Metrics

Debt and Obligations: As of June 30, 2005, the company reported a "Royalty Obligation" of $648,997 (classified as long-term debt under EITF 88-18) and "Deferred License Revenues" of $553,438. There were no outstanding debentures as of this date, having been extinguished in February 2004.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue for the six months ended June 30, 2005, increased to $440,357 from $326,037 in the prior year period. This was driven by a 6% increase in royalty revenue ($314,048 vs. $297,161) and the recognition of $76,484 in grant income from the NIH, which was absent in the prior year.
• Quarterly Royalty Decline: Royalty revenue for the three months ended June 30, 2005, decreased 18% to $148,727 from $181,274 in the prior year quarter. Management attributes this to a decline in large-volume orders from the U.S. Armed Forces and increased price competition from albumin solutions.
• Expense Increases: Research and development (R&D) expenses increased significantly to $804,118 for the six months ended June 30, 2005, compared to $504,753 in the prior year. This $299,365 increase was primarily due to outside research costs ($264,198) and insurance costs ($58,081) associated with the PentaLyte Phase II clinical trial.
• Improved Net Loss: Despite higher R&D spending, the net loss for the six months ended June 30, 2005, improved to $(1,169,324) from $(2,085,210) in the prior year. This improvement is largely due to the absence of a $1.1 million interest expense charge recorded in the first quarter of 2004 related to the extinguishment of debentures.
• Liquidity Position: Cash and cash equivalents decreased by approximately $782,000 during the six-month period, dropping from $1,370,762 at year-end 2004 to $588,540 at June 30, 2005.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash ($588,540) combined with anticipated license fees and royalties is sufficient to fund operations through March 31, 2006. The company has implemented a cost-cutting plan, including voluntary salary decreases and reduced discretionary spending.
• Capital Needs: The company requires additional capital to complete clinical trials for PentaLyte (estimated Phase II cost of $1,000,000) and to continue development of HetaCool. Future financing may involve equity sales, which could result in shareholder dilution.
• Product Pipeline:
  • Hextend: Commercially launched; sales depend on Hospira and CJ Corp. performance.
  • PentaLyte: Currently in Phase II clinical trials for hypovolemia in cardiac surgery. Regulatory approval in the U.S. may require larger, more costly trials than Hextend.
  • HetaCool: Development for low-temperature surgery; funded partially by an NIH grant ($299,990 total).
• Risks: Significant risks include the uncertainty of clinical trial results, the ability to obtain FDA and foreign regulatory approvals, competition from other plasma expanders, and the availability of additional financing. The company also faces risks related to the timing and volume of sales by its licensees, particularly the U.S. Armed Forces.
• Unusual Items: The company entered into a new five-year lease for its corporate headquarters in Emeryville, California, in June 2005. Additionally, a royalty obligation of $648,997 was recorded related to a co-development agreement for the Japanese market, treated as debt rather than revenue.

Investor Verification Checklist

• Cash Runway: Verify if the company can indeed operate through March 31, 2006, given the current cash balance of $588,540 and ongoing burn rate.
• PentaLyte Trial Costs: Confirm the actual costs and timeline for the Phase II clinical trial, as estimates are subject to change and could require immediate capital raising.
• Licensor Performance: Monitor sales reports from Hospira and CJ Corp., as BioTime's revenue is entirely dependent on these partners' performance and reporting schedules.
• Debt Obligations: Review the terms of the "Royalty Obligation" ($648,997) and the impact of the 12% accrued interest on future cash flows.
• Equity Dilution: Assess the potential dilution from outstanding warrants (approx. 3.15 million shares) and options (approx. 1.21 million shares) if the company raises additional equity capital.